The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Open accessAbstract
Inhibiting protein function selectively is a major goal of modern drug discovery. Here, we report a previously understudied benefit of small molecule proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degradation. Using promiscuous CRBN- and VHL-recruiting PROTACs that bind >50 kinases, we show that only a subset of bound targets is degraded. The basis of this selectivity relies on protein-protein interactions between the E3 ubiquitin ligase and the target protein, as illustrated by engaged proteins that are not degraded as a result of unstable ternary complexes with PROTAC-recruited E3 ligases. In contrast, weak PROTAC:target protein affinity can be stabilized by high-affinity target:PROTAC:ligase trimer interactions, leading to efficient degradation. This study highlights design guidelines for generating potent PROTACs as well as possibilities for degrading undruggable proteins immune to traditional small-molecule inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, possible off-target effects may arise from the E3 ligase ligand side, such as the degradation of GSPT1 in this work and others[42–44].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [42]
In the citing paper
“In addition, Bondeson et al. showed that a promiscuous ligand for about 50 kinases could induce only a subset of its targets for degradation when converted into a PROTAC45.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [45]
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [65]
In the citing paper
“Multiple studies have reported that the stability of the E3-degrader-POI ternary complex may influence degradation kinetics and selectivity, and may be a more reliable predictor for degradation than target engagement alone (Bondeson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Bondeson et al., 2018
In the citing paper
“The propensity of different E3 ligases to ubiquitinate specific proteins has been reported to vary in the literature (Bondeson et al., 2018; Smith et al., 2019) and variation is attributed to the unique protein-protein interactions that may form between the E3 ligase and target.”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Bondeson et al., 2018
In the citing paper
“PROTACs are small molecules with two functional ends, wherein one end binds to the protein of interest while the other binds to an E3 ubiquitin ligase (2, 3), bringing the ubiquitin ligase to the target protein, leading to its ubiquitination and subsequent degradation by the proteasome.”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [2]
In the citing paper
“Addition of a linker with a moiety to recruit either VHL or CRBN reduced foretinib’s inhibition for several of these kinases, but overall both PROTACs retained broad non-selective inhibition.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“It has been shown that a PROTAC’s ability to bind the target protein is not the primary determinant of whether efficient degradation occurs; rather, it has been suggested that formation of the ternary complex is limiting (i.e., the ability of the PROTAC to simultaneously bind both the target protein and the E3 ligase) 20, 22.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“Moreover, the extent to which different kinases were degraded was not simply a reflection related to how tightly the PROTAC bound the kinase, since inhibition constants were not correlated with cellular degradation 20.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“Using a competitive binding assay, foretinib itself was first shown to inhibit at least a quarter of the human kinome 20.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“Remarkably, however, cellular treatment revealed that certain kinases were degraded much more efficiently by the VHL-recruiting PROTAC, while others were degraded more efficiently by the CRBN-recruiting PROTAC 20.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“It has further been shown that PROTAC selectivity does not necessarily mimic that of its target-binding warhead, but rather depends sensitively on the linker 20, 23, 24, 33”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“PROTACs may also benefit from cooperative PPIs between the E3 ligase and the POI. This can have the advantages of improved potency49 and selectivity50.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [49]
In the citing paper
“the pairing of VHL versus CRBN for a given target can result in different degradation efficiencies49, as was first observed when targeting the fusion oncogene BCR–ABL by PROTACs118.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [49]
In the citing paper
“In addition, many PROTACs are not completely selective and can degrade proteins other than their desired targets [7, 90, 204, 205].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [204]
In the citing paper
“A major advantage of VHL-based PROTACs is their target-specificity [44, 53].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [53]
In the citing paper
“high binary binding affinities are not necessarily needed to result in efficient degradation of a target protein [53]”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [53]
In the citing paper
“using the same promiscuous kinase inhibitor as a warhead, the CRBN-based PROTAC degrades more kinases than the VHL-based PROTAC [53].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [53]
In the citing paper
“and several PROTACs have been found to be more selective than the inhibitor from which they were derived 12,28,29,30 ,”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citationA quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. J. W. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,867
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 965
Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
Liu, J., Peng, Y., & Wei, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.678077 · Cited by 38
The clinical advances of proteolysis targeting chimeras in oncology
Xie, H., Liu, J., Alem, D., & Fleming, J. B. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00061 · Cited by 38
Designing HDAC-PROTACs: Lessons Learned So Far
Fischer, F., Avelar, L. A. A., Murray, L., & Kurz, T. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0206 · Cited by 38
Targeted protein degraders march towards the clinic for neurodegenerative diseases
Kumar, D., & Hassan, M. I. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101616 · Cited by 38
Design, synthesis and biological evaluation of KRASG12C-PROTACs
Zhang, X., Zhao, T., Sun, M., Li, P., Lai, M., Xie, L., Chen, J., Ding, J., Xie, H., Zhou, J., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117153 · Cited by 38
Targeted protein degradation at the host–pathogen interface
Grohmann, C., Marapana, D. S., & Ebert, G. (2021) · Molecular Microbiology · doi:10.1111/mmi.14849 · Cited by 38
Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives
Li, J., Cai, Z., Li, X., & Zhuang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01223 · Cited by 39
Targeting SWI/SNF Complexes in Cancer: Pharmacological Approaches and Implications
Dreier, M. R., Walia, J., & de la Serna, I. L. (2024) · Epigenomes · doi:10.3390/epigenomes8010007 · Cited by 39
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution
Xiao, Y., Yuan, Y., Liu, Y., Lin, Z., Zheng, G., Zhou, D., & Lv, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00723 · Cited by 39
Targeting glucocorticoid receptor signaling pathway for treatment of stress-related brain disorders
Göver, T., & Ślęzak, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00654-w · Cited by 45
Substrate selection by the proteasome through initiation regions
Tomita, T., & Matouschek, A. T. (2019) · Protein Science · doi:10.1002/pro.3642 · Cited by 39
A kinetic proofreading model for bispecific protein degraders
Bartlett, D. W., & Gilbert, A. M. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09722-z · Cited by 38
Wolter, M., Valenti, D., Cossar, P. J., Hristeva, S., Levy, L. M., Genski, T., Hoffmann, T., Brunsveld, L., Tzalis, D., & Ottmann, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00401 · Cited by 38
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., Hassan, Z., Schneider, C., Patricia Gloria Schäfer, A., Pongratz, H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105505 · Cited by 37
PROTAC: targeted drug strategy. Principles and limitations
Koroleva, O. A., Dutikova, Y. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., & Kurkin, A. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3659-z · Cited by 38
RAS degraders: The new frontier for RAS-driven cancers
Escher, T. E., & Satchell, K. J. F. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.017 · Cited by 36
TAC‐tics for Leveraging Proximity Biology in Drug Discovery
Nalawansha, D. A., Mangano, K., den Besten, W., & Potts, P. R. (2023) · ChemBioChem · doi:10.1002/cbic.202300712 · Cited by 36
Kelly, L. M., Rutter, J. C., Lin, K., Ling, F., Duchmann, M., Latour, E., Arang, N., Pasquer, H., Ho‐Nhat, D., Charles, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00782-5 · Cited by 41
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs
Mamun, M. A. A., Bakunts, A. G., & Chernorudskiy, A. L. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01703-4 · Cited by 41
Lu, A. S., Rouhimoghadam, M., Arnatt, C. K., Filardo, E. J., & Salem, A. K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00018 · Cited by 40
Fischer, P. D., Papadopoulos, E., Dempersmier, J. M., Wang, Z., Nowak, R. P., Donovan, K. A., Kalabathula, J., Gorgulla, C., Junghanns, P., Kabha, E., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113435 · Cited by 37
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
Madan, J., Ahuja, V. K., Dua, K., Samajdar, S., Ramchandra, M., & Giri, S. (2022) · BioDrugs · doi:10.1007/s40259-022-00551-9 · Cited by 37
Wang, F., Zhan, Y., Li, M., Wang, L., Zheng, A., Liu, C.-B., Wang, H., & Wang, T. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00165 · Cited by 36
Targeted Protein Degradation: Design Considerations for PROTAC Development
Tran, N. L., Leconte, G. A., & Ferguson, F. M. (2022) · Current Protocols · doi:10.1002/cpz1.611 · Cited by 35
Scaffold hopping enables direct access to more potent PROTACs with in vivo activity
Burslem, G. M., Bondeson, D. P., & Crews, C. M. (2020) · Chemical Communications · doi:10.1039/d0cc02201b · Cited by 35
Self-citationSelective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases
Aublette, M. C., Harrison, T. A., Thorpe, E. J., & Gadd, M. S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128636 · Cited by 35
Macabuag, N., Esmieu, W., Breccia, P., Jarvis, R. E., Blackaby, W., Lazari, O., Urbonas, L., Eznarriaga, M., Williams, R., Strijbosch, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01149 · Cited by 35
Key Considerations in Targeted Protein Degradation Drug Discovery and Development
Qin, L., Dai, H., & Wang, J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.934337 · Cited by 35
Self-citationChemically induced degradation of epigenetic targets
Kabir, M., Yu, X., Kanıskan, H. Ü., & Jin, J. J. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00100h · Cited by 36
Selective Modulation of Dynamic Protein Complexes
Garlick, J. M., & Mapp, A. K. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.019 · Cited by 39
Identification and characterization of cancer vulnerabilities via targeted protein degradation
Mayor-Ruiz, C., & Winter, G. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.003 · Cited by 33
Tan, L., & Gray, N. S. (2018) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201800293 · Cited by 34
Chaudhry, C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02076 · Cited by 35
Miñarro-Lleonar, M., Bertran‐Mostazo, A., Duro, J., Barril, X., & Juárez‐Jiménez, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01692 · Cited by 31
Structural and functional annotation of solute carrier transporters: implication for drug discovery
Dvorak, V., & Superti‐Furga, G. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2244760 · Cited by 34
From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
Wang, S., He, F., Tian, C., & Sun, A. (2024) · Pharmaceuticals · doi:10.3390/ph17010100 · Cited by 34
He, T., Cheng, C., Qiao, Y., Cho, H., YOUNG, E. A., Mannan, R., Mahapatra, S., Miner, S. J., Zheng, Y., Kim, N. H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322563121 · Cited by 30
Methods to accelerate PROTAC drug discovery
Osman, J., Thompson, P. E., Jörg, M., & Scanlon, M. J. (2025) · Biochemical Journal · doi:10.1042/bcj20243018 · Cited by 34
Pathak, P., Rimac, H., Grishina, M., Verma, A., & Potemkin, V. (2020) · ChemMedChem · doi:10.1002/cmdc.202000646 · Cited by 32
Targeted Protein Degradation: Clinical Advances in the Field of Oncology
Salama, A. K. A. A., Trkulja, M. V., Casanova, E., & Uras, I. Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315440 · Cited by 36
Could PROTACs Protect Us From COVID-19?
Martinez‐Ortiz, W., & Zhou, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.08.007 · Cited by 32
Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV
Newton, L. S., Gathmann, C., Ridewood, S., Smith, R. J., Wijaya, A. J., Hornsby, T. W., Morling, K. L., Davison, D., Chiozzi, R. Z., Reuschl, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56317-8 · Cited by 34
Toward Development of the Male Pill: A Decade of Potential Non-hormonal Contraceptive Targets
Kent, K., Johnston, M., Strump, N., & Garcia, T. X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00061 · Cited by 32
Small-molecule PROTACs: Novel Agents for Cancer Therapy
Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 32
Makukhin, N., & Ciulli, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00272k · Cited by 31
PROTACs technology for targeting non-oncoproteins: Advances and perspectives
Wang, C., Zhang, Y., Xing, D., & Zhang, R. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105109 · Cited by 32
Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death
Chang, S. C., Gopal, P., Lim, S., Wei, X., Chandramohan, A., Mangadu, R., Smith, J., Ng, S., Gindy, M., Phan, U., et al. (2022) · Cell Chemical Biology · doi:10.1016/j.chembiol.2022.10.005 · Cited by 31
Unifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms
Rodriguez-Rivera, F. P., & Levi, S. M. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00389 · Cited by 30
Recent advances in the development of deubiquitinases inhibitors as antitumor agents
Zheng, L., Wang, L., Pang, Y.-W., Sun, L., & Shi, L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116161 · Cited by 29
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Saleem, R. S. Z., Schwalm, M. P., & Knapp, S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117718 · Cited by 31
Stevens, R., Shrives, H. J., Cryan, J., Klimaszewska, D., Stacey, P., Burley, G. A., Harling, J. D., Battersby, D. J., & Miah, A. H. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00760c · Cited by 34
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics
Ou, L., Setegne, M. T., Elliot, J., Shen, F., & Dassama, L. M. K. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00595 · Cited by 33
Construction of an IMiD-based azide library as a kit for PROTAC research
Liu, H., Sun, R., Ren, C., Qiu, X., Yang, X., & Jiang, B. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02120b · Cited by 30
Song, J. H., Wagner, N. D., Yan, J. R., Li, J., Huang, R. Y. ‐., Balog, A., Newitt, J. A., Chen, G., & Gross, M. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.005 · Cited by 31
Fu, L., Zhang, J., Shen, B., Kong, L., Liu, Y., Tu, W., Wang, W., Cai, X., Wang, X., Cheng, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00103 · Cited by 29
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Su, J., Xiao, Y., Wei, L., Lei, H., Sun, F., Wang, W., Yin, J., Xiong, R., Li, S., Zhang, P., et al. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.01.019 · Cited by 30
Self-citationAbbas, A., & Ye, F. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134293 · Cited by 29
A comprehensive review of emerging approaches in machine learning for de novo PROTAC design
Gharbi, Y., & Mercado, R. (2024) · Digital Discovery · doi:10.1039/d4dd00177j · Cited by 32
Unleashing the Power of Covalent Drugs for Protein Degradation
Fu, M., Jin, H., Wang, S., Shen, L., Liu, H., Liu, Y., Zheng, Y., & Dai, X. (2025) · Medicinal Research Reviews · doi:10.1002/med.22101 · Cited by 31
Riching, K. M., Mahan, S. D., Urh, M., & Daniels, D. L. (2020) · Journal of Visualized Experiments · doi:10.3791/61787 · Cited by 30
Chernobrovkin, A. L., Cázares-Körner, C., Friman, T., Caballero, I. M., Amadio, D., & Molina, D. M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220984372 · Cited by 28
Ege, N., Bouguenina, H., Tatari, M. N., & Chopra, R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.011 · Cited by 31
Structure‐Based Design of a Macrocyclic PROTAC
Testa, A., Hughes, S. J., Lucas, X., Wright, J. E., & Ciulli, A. (2019) · Angewandte Chemie · doi:10.1002/ange.201914396 · Cited by 34
Molecular glues: enhanced protein-protein interactions and cell proteome editing
Weagel, E. G., Foulks, J. M., Siddiqui, A. Q., & Warner, S. L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02882-2 · Cited by 31
Chen, J., Ji, P., Gnawali, G. R., Chang, M., Gao, F., Xu, H., & Wang, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.018 · Cited by 29
Liu, H., Li, Z., Reindl, T., He, Z., Qiu, X., Golden, R. P., Donovan, K. A., Bailey, A. L., Fischer, E. S., Zhang, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49161-9 · Cited by 30
Principles of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2
Scott, D. C., Dharuman, S., Griffith, E. C., Chai, S. C., Ronnebaum, J., King, M. T., Tangallapally, R. P., Lee, C., Gee, C. T., Yang, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52966-3 · Cited by 29
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions
Vikal, A., Maurya, R., Patel, B. B., Sharma, R. K., Patel, P., Patil, U. K., & Kurmi, B. D. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01754-z · Cited by 29
Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
Nguyen, K. M., & Busino, L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.007 · Cited by 29
The application of ubiquitin ligases in the PROTAC drug design
Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 29
Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?
Powell, M., Blaskovich, M. A. T., & Hansford, K. A. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00203 · Cited by 29
Recent advances in induced proximity modalities
Ng, C. S. C., & Banik, S. M. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102107 · Cited by 27
Huang, Y., Yokoe, H., Kaiho-Soma, A., Takahashi, K., Hirasawa, Y., Morita, H., Ohtake, F., & Kanoh, N. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00490 · Cited by 28
Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
Yuan, M., Chu, Y., & Duan, Y. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.691093 · Cited by 27
Targeted protein degradation as an antiviral approach
Chakravarty, A., & Yang, P. L. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105480 · Cited by 28
Central Nervous System Targeted Protein Degraders
Thomas, B. A. I., Lewis, H. L., Jones, D. H., & Ward, S. E. (2023) · Biomolecules · doi:10.3390/biom13081164 · Cited by 30
Liang, X., Ren, H., Han, F., Liang, R., Zhao, J., & Liu, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21992 · Cited by 31
Strategy and Design of In Situ Activated Protein Hydrolysis Targeted Chimeras
Lv, M.-Y., Hou, D., Liu, S., Cheng, D., & Wang, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c11903 · Cited by 30
Emerging modes-of-action in drug discovery
Valeur, E., Narjes, F., Ottmann, C., & Plowright, A. T. (2019) · MedChemComm · doi:10.1039/c9md00263d · Cited by 29
Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine
Engelberg, I. A., Foley, C. A., James, L. I., & Frye, S. V. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.03.002 · Cited by 26
Selective degradation-inducing probes for studying cereblon (CRBN) biology
Powell, C. E., Du, G., Bushman, J. W., He, Z., Zhang, T., Fischer, E. S., & Gray, N. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00382d · Cited by 29
Selection for constrained peptides that bind to a single target protein
King, A. M., Anderson, D. A., Glassey, E., Segall-Shapiro, T. H., Zhang, Z., Niquille, D. L., Embree, A., Pratt, K., Williams, T. L., Gordon, D. B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26350-4 · Cited by 27
Tang, R., Wang, Z., Xiang, S., Wang, L., Yu, Y., Wang, Q., Deng, Q., Hou, T., & Sun, H. (2023) · JACS Au · doi:10.1021/jacsau.3c00195 · Cited by 28
Reversible Assembly of Proteolysis Targeting Chimeras
Gui, W., Giardina, S. F., Balzarini, M., Barany, F., & Kodadek, T. J. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00199 · Cited by 27
Muddassir, M., Soni, K. V., Sangani, C. B., AlArifi, A. S., Afzal, M. F., Abduh, N. A. Y., Duan, Y., & Bhadja, P. (2020) · RSC Advances · doi:10.1039/d0ra07971e · Cited by 27
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Bouvier, C., Lawrence, R., Cavallo, F., Xolalpa, W., Jordan, A. M., Hjerpe, R., & Rodríguez, M. S. (2024) · Cells · doi:10.3390/cells13070578 · Cited by 28
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Kuemper, S., Cairns, A. G., Birchall, K., Yao, Z., & Large, J. M. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1370509 · Cited by 32
Yamashita, H., Tomoshige, S., Nomura, S., Ohgane, K., Hashimoto, Y., & Ishikawa, M. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115175 · Cited by 26
Exosome‐mediated PROTACs delivery to target viral infections
Mukerjee, N., Maitra, S., Ghosh, A., Subramaniyan, V., & Sharma, R. (2023) · Drug Development Research · doi:10.1002/ddr.22091 · Cited by 26
Bagka, M., Choi, H., Héritier, M., Schwaemmle, H., Pasquer, Q. T. L., Braun, S. M. G., Scapozza, L., Wu, Y., & Hoogendoorn, S. (2023) · Nature Communications · doi:10.1038/s41467-023-39657-1 · Cited by 27
Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation
Mader, M. M., Rudolph, J., Hartung, I. V., Uehling, D., Workman, P., & Zuercher, W. J. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0536 · Cited by 25
Liver-targeting chimeras as a potential modality for the treatment of liver diseases
Chen, C., Pan, Y., Yang, X., Li, H., Cai, X., He, S., Wang, Q., Yang, Y., Zheng, R., Li, H., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.044 · Cited by 25
Chemical proteomics accelerates the target discovery of natural products
He, S., Li, J., Zhou, J.-C., Yang, Z., Liu, X., & Ge, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116609 · Cited by 25
EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities
Toracchio, L., Carrabotta, M., Mancarella, C., Morrione, A., & Scotlandi, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212191 · Cited by 28
Protein Ligand Interactions Using Surface Plasmon Resonance
O’Connell, N. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_1 · Cited by 25
Riching, K. M., Vasta, J. D., Hughes, S. J., Zoppi, V., Maniaci, C., Testa, A., Urh, M., Ciulli, A., & Daniels, D. L. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100009 · Cited by 26
PROTAC chemical probes for histone deacetylase enzymes
Patel, U., Smalley, J. P., & Hodgkinson, J. T. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00105a · Cited by 25
A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα
Jauslin, W. T., Schild, M., Schaefer, T., Borsari, C., Orbegozo, C., Bissegger, L., Zhanybekova, S., Ritz, D., Schmidt, A., Wymann, M. P., et al. (2023) · Chemical Science · doi:10.1039/d3sc04629j · Cited by 25
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
Pacini, L., Jenks, A. D., Vyse, S., Wilding, C. P., Arthur, A., & Huang, P. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s242045 · Cited by 27
Metadata
- Authors
- Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M.
- Affiliations
- Yale University (US)
- Arvinas (United States) (US)
- Corresponding author
- Crews, Craig M.
- ORCID
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 25
- Issue
- 1
- Pages
- 78-87.e5
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- PMC
- PMC5777153
- OpenAlex
- W2767856718
- Cited by
- 923
- References
- 50
- Citations by year
- 2026: 104 · 2025: 133 · 2024: 147 · 2023: 104 · 2022: 110 · 2021: 110 · 2020: 109 · 2019: 72 · 2018: 29
- FWCI
- 23.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell chemical biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NCI (F99 CA212229-02, R50 CA211252-02)
- Leukemia and Lymphoma Society Career Development
- NIH (R35CA197589)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, protein degradation, E3 ubiquitin ligase, cereblon, VHL, protein-protein interaction, ternary complex stability, PROTAC design, undruggable proteins, ubiquitination, proteasome
- MeSH terms
- Humans, Drug Design, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Protein Kinase Inhibitors, Small Molecule Libraries, Ubiquitination, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
